Evidence map›Paper›PMID 40978200›Full record

ArticleBiochemistry and biophysics reports2025

OT17 a novel microsatellite stable colorectal cancer cell line and organoid model for investigating

Chen Zheng, Xuan Tang, Shuang Wang, Yuxuan Xu, Keyang Jia, Ganglong Gao, Guiying Wei, Gengming Niu, Yiwen Wu, Xiaozhe Qian and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chen ZhengState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Jiaotong University, Shanghai, PR China.
Xuan TangDepartment of Oncology, The Sixth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200233, PR China.
Shuang WangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Jiaotong University, Shanghai, PR China.
Yuxuan XuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Jiaotong University, Shanghai, PR China.
Keyang JiaState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Jiaotong University, Shanghai, PR China.
Ganglong GaoDepartment of Biliary-Pancreatic Surgery, Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Guiying WeiShanghai OneTar Biomedicine, Shanghai, PR China.
Gengming NiuShanghai OneTar Biomedicine, Shanghai, PR China.
Yiwen WuBeijing National Day School, Shanghai, PR China.
Xiaozhe QianDepartment of Thoracic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China.
Ying ZhuDepartment of Oncology, Fengxian District Central Hospital, The Sixth People's Hospital South Campus Affiliated to Shanghai Jiao Tong University, Shanghai, PR China.
Dongxi XiangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Jiaotong University, Shanghai, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human cancer cell lines serve as essential in vitro models for investigating tumor biology, carcinogenesis, molecular genetics, metastasis, and tumor evolution. In this study, we establish and characterize the OT17 cell line, derived from a moderately to poorly differentiated colorectal adenocarcinoma surgical specimen. Genetic analysis of OT17 revealed key mutations, including BRAF V600E, APC, and ERBB2, along with a deletion in TP53. Immunohistochemical profiling confirmed the expression of MLH1, MSH2, MSH6, and PMS2, indicating a microsatellite-stable (MSS) phenotype consistent with the primary tumor. The OT17 cell line demonstrated robust tumorigenicity in vivo, achieving a 100 % success rate in forming subcutaneous tumors in NOD-scid Il2rg

Indexed as

Cell lineColorectal cancerOrganoidTumorigenicity

Identifiers

PMID40978200
PMCPMC12446196

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.